A cost analysis of early discharge and domiciliary visits versus standard hospital care for low-risk obstetric clients

2010 ◽  
Vol 18 (1) ◽  
pp. 96-100 ◽  
Author(s):  
Anthony Scott
2020 ◽  
Vol 226 ◽  
pp. 96-105.e7 ◽  
Author(s):  
Tetsuya Isayama ◽  
Daria O'Reilly ◽  
Joseph Beyene ◽  
Prakesh S. Shah ◽  
Shoo K. Lee ◽  
...  

2011 ◽  
Vol 35 (4) ◽  
pp. 491 ◽  
Author(s):  
Senthil Lingaratnam ◽  
Leon J. Worth ◽  
Monica A. Slavin ◽  
Craig A. Bennett ◽  
Suzanne W. Kirsa ◽  
...  

Background. Adult febrile neutropenic oncology patients, at low risk of developing medical complications, may be effectively and safely managed in an ambulatory setting, provided they are appropriately selected and adequate supportive facilities and clinical services are available to monitor these patients and respond to any clinical deterioration. Methods. A cost analysis was modelled using decision tree analysis, published cost and effectiveness parameters for ambulatory care strategies and data from the State of Victoria’s hospital morbidity dataset. Two-way sensitivity analyses and Monte Carlo simulation were performed to evaluate the uncertainty of costs and outcomes associated with ambulatory care. Results. The modelled cost analysis showed that cost savings for two ambulatory care strategies were ~30% compared to standard hospital care. The weighted average cost saving per episode of ‘low-risk’ febrile neutropenia using Strategy 1 (outpatient follow-up only) was 35% (range: 7–55%) and that for Strategy 2 (early discharge and outpatient follow-up) was 30% (range: 7–39%). Strategy 2 was more cost-effective than Strategy 1 and was deemed the more clinically favoured approach. Conclusion. This study outlines a cost structure for a safe and comprehensive ambulatory care program comprised of an early discharge pathway with outpatient follow-up, and promotes this as a cost effective approach to managing ‘low-risk’ febrile neutropenic patients. What is known about the topic? Febrile neutropenia is a common complication of chemotherapy for patients with cancer. There is high level evidence supporting the use of ambulatory care strategies to manage patients with febrile neutropenia who are deemed to be at low risk of developing medical complications. What does this paper add? This paper highlights a cost structure for an adequately equipped and cost-effective ambulatory care strategy suitable for Australian hospitals to manage patients with low-risk febrile neutropenia. What are the implications for practitioners? The strategy advocated in this paper affords eligible patients the choice of early discharge from hospital. It advocates for improved resource utilisation and expansion of outpatient services in order to minimise opportunity costs faced by cancer treatment facilities.


Global Heart ◽  
2018 ◽  
Vol 13 (4) ◽  
pp. 421-422
Author(s):  
T.W. Lim ◽  
S.T. Karim ◽  
M. Fernando ◽  
J. Haydar ◽  
R. Lightowler ◽  
...  
Keyword(s):  

PLoS ONE ◽  
2016 ◽  
Vol 11 (8) ◽  
pp. e0161493 ◽  
Author(s):  
Marie-Eva Laurencet ◽  
François Girardin ◽  
Fabio Rigamonti ◽  
Anne Bevand ◽  
Philippe Meyer ◽  
...  

Midwifery ◽  
1996 ◽  
Vol 12 (2) ◽  
pp. 85-92 ◽  
Author(s):  
Linda J. Kvist ◽  
Eva Persson ◽  
Göran K. Lingman

1990 ◽  
Vol 8 (12) ◽  
pp. 1998-2004 ◽  
Author(s):  
C A Mullen ◽  
G R Buchanan

Children with leukemia and solid tumors are often hospitalized for empiric broad-spectrum antibiotic therapy because of fever during periods of chemotherapy-induced neutropenia. Conventional practice dictates that parenteral antibiotics be continued until the patient is afebrile and has recovered from neutropenia, ie, until the absolute neutrophil count (ANC) exceeds 500 cells per cubic millimeter. However, the practice in our center has been to discontinue parenteral antibiotic therapy and discharge many such patients before resolution of neutropenia. Since the feasibility and safety of this approach has not been studied, we reviewed the records of 114 consecutive hospitalizations for fever and neutropenia in 61 patients during a 13-month period. Seventy-seven children (68%) were discharged to their homes while still neutropenic after they had been afebrile for 1 to 2 days on parenteral antibiotics, had negative blood cultures, appeared well, and usually had some evidence of bone marrow recovery. Five patients (4.4%) developed recurrent fever and required rehospitalization within 7 days of discharge. Only three of the 77 patients (3.9%) who were sent home with neutropenia had recurrent fever. Each had a brief and uneventful second hospitalization. Two of the 37 children discharged with an ANC over 500 cells per cubic millimeter required rehospitalization. A declining ANC and advanced malignancy were risk factors in predicting recurrence of fever following discharge. A rising monocyte count was a predictor of imminent recovery from neutropenia. These results suggest that "early" discharge of an afebrile yet still neutropenic patient is safe when the patient is in remission, has no evidence of serious infection, appears clinically stable, and has indications of bone marrow recovery. The conventional approach of routinely continuing the hospitalization until resolution of neutropenia may be unnecessary in such low-risk patients.


Sign in / Sign up

Export Citation Format

Share Document